Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Working Capital Changes (2016 - 2025)

CytomX Therapeutics' Other Working Capital Changes history spans 12 years, with the latest figure at -$66.0 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 19790.75% year-over-year to -$66.0 million; the TTM value through Dec 2025 reached -$65.6 million, down 4477.53%, while the annual FY2025 figure was -$65.6 million, 4477.53% down from the prior year.
  • Other Working Capital Changes reached -$66.0 million in Q4 2025 per CTMX's latest filing, down from -$708000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $62.3 million in Q4 2023 to a low of -$66.0 million in Q4 2025.
  • Average Other Working Capital Changes over 5 years is -$4.3 million, with a median of -$8.1 million recorded in 2021.
  • Peak YoY movement for Other Working Capital Changes: skyrocketed 339.21% in 2022, then tumbled 1741000.0% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$10.3 million in 2021, then soared by 260.24% to $16.6 million in 2022, then skyrocketed by 275.66% to $62.3 million in 2023, then plummeted by 99.46% to $335000.0 in 2024, then tumbled by 19790.75% to -$66.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Other Working Capital Changes are -$66.0 million (Q4 2025), -$708000.0 (Q3 2025), and $45.7 million (Q2 2025).